BCL11A and sickle cell disease: Overall, efforts from the last decades have shed enough light on the mechanisms that orchestrate hemoglobin switching for developing gene therapy approaches targeting such discovered regulators (e.g., BCL11A, ZNF410) for sickle cell disease and β-thalassemia.